Short answer
Biohaven Ltd. (BHVN) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation at Jefferies Global Healthcare Conference, London, November 16-19.
Biohaven Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation at Jefferies Global Healthcare Conference, London, November 16-19
- Exhibit 99.1 contains Biohaven’s conference materials, potentially relevant for pipeline and corporate updates
Item EX-99.1 · Exhibit EX-99.1
- November 2026 corporate presentation highlights Biohaven’s protein-degrader platform and broad pipeline across autoimmune disease, epilepsy, pain, oncology, and neurology
- BHV-1300 Graves’ disease Phase 3 initiated, following preliminary data showing over 80% TSHR autoantibody reduction and hormone normalization within 3 to 5 weeks
- BHV-1400 IgA nephropathy Phase 3 planned for 2026, with 500 mg dosing and 420 planned participants across treatment and placebo arms
- Protein-degrader platform claims over 2M addressable U.S. patients, 8+ programs, and $30B+ combined peak-sales potential, all management estimates
- Opakalim data showed median time to second generalized tonic-clonic seizure of 141 days versus 47 days for placebo, but the study terminated early for strategic prioritization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biohaven Ltd. 8-K filings
Get the next BHVN 8-K as it lands
Follow BHVN for push alerts, or ask the research agent what this filing means.